Moderna, Inc. (MRNA) shares fell 1.7% to $221.09 as of October 12, 2026, a modest decline from the prior close of $225.00. BestStocks flagged the session as a major change for MRNA. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
MRNA fell 1.7% to $221.09
MRNA fell 1.7% in its latest session, moving from $225.00 to $221.09.
ValuationWeak confidence
Rel. volume
0.4×
Below Avg
Vs peers
—
No comparable peers
Market cap
$87.7B
NASDAQ Global Select
Analyst target
$116
-47.7% vs price
Price chart
Sep 11 – Oct 12
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Moderna rallied 6.10% to $201.60 on index inclusion momentum and pipeline optimism; Positive price momentum. Weighing against that: Material negative event; Negative session, down 1.7%. Wall Street's consensus price target sits at $115.70, implying -47.7% downside from $221.09. Over the past 90 days analysts logged 3 upgrades and 2 downgrades. BestStocks rates the overall signal quality weak (37/100). With earnings roughly 24 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $221.09, down $3.92 (-1.74%) from the previous close of $225.00. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $143.77 and $225.00, and it currently sits about 95% of the way up that band.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $115.70, 47.7% below the recent $221.09. Over the past 90 days analysts logged 3 upgrades, 8 maintains, and 2 downgrades. Here is how the bullish and bearish cases on MRNA line up.
▲ The bullish case
+The Street's most bullish target is $245.00 (+10.8%).
+3 analyst upgrades in the past 90 days, most recently Argus Research to Buy (2026-08-28).
+Moderna rallied 6.10% to $201.60 on index inclusion momentum and pipeline optimism.
+Positive price momentum.
▼ The bearish case
−The consensus analyst price target of $115.70 sits 47.7% below the recent $221.09, so the average target sees limited room to run.
−The most bearish analyst target is $25.00 (-88.7%).
−2 analyst downgrades in the past 90 days, most recently Citigroup to Sell (2026-09-30).
−Material negative event.
−Negative session, down 1.7%.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 12, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Analyst expectations
Consensus target: $116-47.7%
↑ 3 upgrades= 8 maintains↓ 2 downgrades
Morgan Stanley maintained Equal Weight · 2026-10-07
Moderna, Inc. (MRNA) moved +6.99% from $183.65 to $196.48 on 2026-10-07 after Tempus announced an expansion of its multi-year collaboration with Moderna and Merck for V940/mRNA-4157 neoantigen therapy commercialization. The stock also reached a new 52-week high of $211.89 during the trading session.
News2026-10-07+4.8%
Tempus expands multi-year collaboration with Moderna and Merck for V940/mRNA-4157 neoantigen therapy commercialization.
Moderna pulled back 6.23% to $190.56 after hitting a 52-week intraday high of $212.22, driven by profit-taking and a sector-wide vaccine stock cooldown following World Health Organization risk updates that dampened speculative momentum. The retreat also reflects investor caution around stretched valuations and elevated expectations for the oncology pipeline ahead of clinical data releases, as cited by recent Wall Street "Sell" ratings.
Moderna rallied 6.10% to $201.60 on index inclusion momentum and pipeline optimism. The stock is set to join the Nasdaq-100 on October 9, 2026, triggering accumulation by passive funds (per web search synthesis), while investor sentiment remains buoyed by strong Phase 3 results for its personalized melanoma vaccine co-developed with Merck. Volume of 10.3M shares at 230 minutes into the session runs 1.20x normal for this time of day.
Citigroup downgraded Moderna from Neutral to Sell, citing an overextended rally following the melanoma vaccine trial win and arguing current valuations price in unrealistic cross-tumor sales projections (per Seeking Alpha). The stock fell 7.03% to $189.15. Volume was 1.95x expected for this point in the session, and the decline also reflects reported patent litigation headwinds — a federal court denied Moderna's motion to dismiss infringement claims from Bayer's Monsanto unit over foundational mRNA technology.
Moderna, Inc. moved +5.67% intraday from $172.94 to $182.75. Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?: Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna stock [2026-09-22]
Material / Earnings2026-09-22+5.6%
MRNA moved -100.00% from its $168.58 open to a $182.56 close on 2026-09-22.
Moderna surged +13.25% to $174.46 after announcing its Phase 3 melanoma vaccine trial (intismeran autogene, co-developed with Merck) earned a prestigious Presidential Symposium slot at the European Society for Medical Oncology (ESMO) Congress 2026 on October 24. Yahoo Finance and Morningstar cited the announcement as the driver. Medical congresses reserve these slots for practice-changing clinical datasets, and markets interpreted the selection as a strong signal ahead of data presentation.
In-depth MRNA event analyses
Permanent, dated analyses of MRNA's most significant sessions.
MRNA fell 1.7% to $221.09. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MRNA stock fall?
MRNA lost 1.74% ($3.92) versus the prior close of $225.00, last trading at $221.09 on 0.4× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-11-05 — about 24 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $115.70, about 47.7% below the current $221.09. Over the past 90 days, analysts recorded 3 upgrades, 8 maintains, and 2 downgrades.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 12, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
